STOCKS RETREAT WITH FED IN FOCUS, AMAZON EARNINGS ON DECK

U.S. wages increase by most in a year in the first quarter, feed case for Fed to 'take its time'

Ascletis Pharma Inc. (2VJ.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Add to watchlist

0.1480

+0.0150

(+11.28%)

As of 09:59AM CEST. Market open.

Loading interactive chart...

PR Newswire
Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
PR Newswire
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
PR Newswire
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.